CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

ApremilastWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (4)

Name (Synonyms) Correlation
drug629 Cenicriviroc Wiki 1.00
drug2375 Razuprotafib Wiki 1.00
drug1373 Icatibant Wiki 1.00
drug2413 Remdesivir Wiki 0.23

Correlated MeSH Terms (1)

Name (Synonyms) Correlation
D016638 Critical Illness NIH 0.13

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 I-SPY COVID TRIAL: An Adaptive Platform Trial to Reduce Mortality and Ventilator Requirements for Critically Ill Patients

The goal of this project is to rapidly screen promising agents, in the setting of an adaptive platform trial, for treatment of critically ill COVID-19 patients. In this phase 2 platform design, agents will be identified with a signal suggesting a big impact on reducing mortality and the need for, as well as duration, of mechanical ventilation.

NCT04488081 COVID-19 Drug: Remdesivir Drug: Cenicriviroc Drug: Icatibant Drug: Razuprotafib Drug: Apremilast
MeSH:Critical Illness

Primary Outcomes

Description: Time to achieve durable change in COVID-19 to ordinal level 4 or less for at least 48 hours

Measure: Identify agents that will result in substantial improvements to the clinical condition of participants with COVID-19

Time: Up to 28 days

Secondary Outcomes

Description: % of COVID-19 level 5 who never progress to COVID-19 level 6/7

Measure: Improvement in disease severity

Time: Up to 60 days

Description: Ventilator-free Days

Measure: Health care utilization

Time: Up to 60 days

Description: Total grade 3 or higher AEs by arm and total number of patients with grade 3 or higher AEs by arm. ● Total grade 3 or higher AEs of special interest by arm and total number of patients with grade 3 or higher AEs of special interest by arms (based upon lab assessments)

Measure: Frequency of serious AEs

Time: Up to 60 days

Description: Mortality at 28 days after study enrollment

Measure: Mortality

Time: Up to 28 days

No related HPO nodes (Using clinical trials)